Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mesoblast Limited (MESO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Mesoblast LimitedTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Mesoblast Limited vs Neurocrine Biosciences Inc — how do they compare? Mesoblast Limited trades at $16.75 (market cap $2.21B), while Neurocrine Biosciences Inc trades at $156.4 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 7.4× Mesoblast Limited's market cap. Which is the better fit depends on your goals.

MESONBIX
Market Cap
$2.21B$16.46B
Sector
TechnologyHealth
52-Week High
$20.96$185.50
52-Week Low
$12.88$123.10
Enterprise Value
$2.21B$16.48B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mesoblast Limited

MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.

MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.

The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX